FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padc…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...

PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a supplemental Biologics Li ...
Nasdaq

Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer

Positive opinion also granted for KEYTRUDA as part of a perioperative regimen for the treatment of certain adult patients with resectable locally advanced head and neck squamous cell carcinoma ...
CURE

FDA Accepts Application for Padcev Plus Keytruda For Some With Bladder Cancer

The FDA accepted an application for Padcev plus Keytruda for patients with muscle-invasive bladder cancer ineligible for ...
Pharmabiz

US FDA grants priority review for Keytruda & Keytruda Qlex, each in combination with Padcev, for certain patients with muscle-invasive bladder cancer

US FDA grants priority review for Keytruda & Keytruda Qlex, each in combination with Padcev, for certain patients with muscle-invasive bladder cancer: Rahway, New Jersey Friday, O ...

Merck Stock Falls. Sales of Key Products Missed Estimates.

Merck boosts its full-year outlook as third-quarter earnings top estimates following strong demand for its blockbuster cancer ...
Pharmabiz

European Commission approves Merck’s Keytruda as part of a treatment regimen for adults with resectable LA-HNSCC expressing PD-L1

European Commission approves Merck’s Keytruda as part of a treatment regimen for adults with resectable LA-HNSCC expressing PD-L1: Rahway, New Jersey Thursday, October 30, 2025, ...

ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability

MSD and Eisai presented the data at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The data showed there was a five-year overall survival (OS) rate of 16.7% for the ...